The Latest Breaking News from Evommune

Steve Cohen's Point72 Boosts Stake in Beaten-Down Biotech Stock by 5,100% Despite Disappointing Trial Results

Billionaire Steve Cohen still backs biotech Evommune despite trial setbacks, highlighting its potential for treating chronic conditions and its strategic role in his portfolio.

International Business Times UK · Jul 20

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

MarketBeat · Jan 19